A University of Colorado research group led by Dr. Michael Verneris has developed a novel process to create autologous hematopoietic stem cells (HSCs) that are engraftable in patient bone marrow. Human iPS cells are treated with a small molecule (SM1). SM1 changes the gene expression in iPS-derived HSCs, giving them a genetic signature associated with bone marrow engraftment in mice and the associated ability to engraft in mice. In addition, treatment with SM1 resulted in more than two-fold expansion of HSCs over the course of 12 days of culture and led to increased iPSC-derived human HSC engraftment in immune-deficient mice.
Download Summary Document Here:
http://cuamc.technologypublisher.com/files/sites/market_summary_cu4914h.pdf